CONSUMPTION AND USAGE OF CEFUROXIME AT THE DEPARTMENT OF INFECTIOUS OBSTETRICSIN NATIONAL HOSPITAL OF OBSTETRICS AND GYNECOLOGY

Thân Thị Hải Hà, Dương Viết Tuấn, Phan Thị Mỹ Linh

Main Article Content

Abstract

Objectives: This study was conducted to describe the consumption and usage characteristics of cefuroxime at theDepartment of Infectious Obstetricsin National Hospital of Obstetrics and Gynecology in 2019. Methods: The cross-sectional study design was used. The consumption characteristics were assessed through DDD per 100 bed-days, and the usage characteristics were investigated on 179 medical records of inpatients prescribed cefuroxime at the Department of Infectious Obstetrics from January to August in 2019. Results: Cefuroxime has the fourth highest level in this department with 7.97 DDD per 100 bed-days. The pelvic inflammatory disease (endometritis, inflammation and abscess of the uterine appendages), breast abscess were the most common infections, and cefuroxime regimen was chosen as the initial regimen in most of these cases. Conclusion: Cefuroxime consumption ranks 4th at the Department of Infectious Obstetrics in 2019. However, almost cefuroxime regimens used are not included in the treatment guidelines. Doses of cefuroxime should be re-evaluated.

Article Details

References

1. Bệnh viện Từ Dũ (2019), "Phác đồ điều trị sản phụ khoa", pp.
2. Nguyễn Thu Nga (2019), "Khảo sát tình hình tiêu thụ kháng sinh và đề kháng kháng sinh của các vi khuẩn gây bệnh phân lập được tại Bệnh viện phụ sản Trung ương", Khóa luận tốt nghiệp dược sĩ, Đại học Dược Hà Nội, pp.
3. ACOG (2018), "Practice Bulletin No.199: Use of Prophylactic Antibiotics in Labor and Delivery", Obstetrics & Gynecology, 132(3), pp. e103–e119.
4. Antimicrobial Therapy Inc. (2016), The Sanford Guide To Antimicrobial Therapy, pp. 6-78.
5. CDC (2015), "Pelvic Inflammatory Disease, Sexually Transmitted Diseases Treatment Guidelines", pp.
6. Gilles R. G. Monif David A. Baker (2008), Infectious Diseases In Obstetrics And Gynecology, pp. 17.
7. GlaxoSmithKline UK, Summary of Product Characteristics: Zinacef. 2020, Electronic Medicines Compendium (EMC).